HSC™ instrument and process reduces time and cost of protein formulation for drug development
BIRMINGHAM, Ala., Oct. 9, 2012 /PRNewswire/ -- Birmingham-based Soluble Therapeutics, Inc, today announced the official launch of its high-throughput second viral coefficient determination system, HSC™ Technology, at the IBC BioProcess International Conference in Providence, RI October 8-12.
HSCTM Technology was developed by Dr. Bill Wilson, former Chairman, Chemistry Department at Mississippi State University, and former NASA astronaut, Dr. Larry DeLucas, Director of the Center for Biophysical Sciences & Engineering at the University of Alabama Birmingham. Doctors Wilson and DeLucas have collaborated for the last two decades on the development of the HSC™ Technology. http://www.youtube.com/watch?v=J1PwehpiV-I.
"Conventional methods used to identify formulations promoting solubility and stability of proteins often cost hundreds of thousands of dollars," said Dr. Joseph N. Garner, CEO, Soluble Therapeutics. Inc. "HSC™ Technology accelerates the formulation process, achieving in a month what can take a team of scientists a year or longer to achieve. Since significantly less protein is required for optimization, HSC™ is an incredibly efficient way to get past the formulation bottleneck."
Companies developing biotherapeutics face the challenge of keeping therapeutic proteins soluble and stable at high concentrations. The HSC™ system helps researchers and manufacturers overcome this challenge by reducing time and costs, while accelerating the progression of candidates through the development pipeline.
HSC™ Technology is a self-contained, automated, chromatographic system that conducts high-throughput, microcapillary, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations. The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination(s) of additives and excipients, resulting in increased solubility and physical stability of proteins. The system works in concert with a predictive algorithm of formulation parameters that can be exclusively accessed through Soluble Therapeutics.
The HSC™ Instrument, and underlying technology, has been validated over the past ten years via industry and academic collaborations. For biopharmaceutical clients this means faster development times and quicker progression of molecules into the clinic. For academic collaborators, this has meant further progression of structural biology studies necessary to advance research in areas of unmet medical need.
Soluble Therapeutics, Inc. has received over $1 million in grant funding from the National Institutes of Health, which is being utilized to advance applications of the HSC™ Technology.
About Soluble Therapeutics, Inc.
Soluble Therapeutics, Inc. was founded in 2008 to commercialize the HSC™ Technology. The company's services enhance the drug development process, by rapidly optimizing protein solubility and stability. Soluble Therapeutics brings transformational technology to the world of protein-based pharmaceuticals, vaccines, and therapeutics. Led by CEO Dr. Joseph N. Garner, Soluble Therapeutics' management team consists of science industry professionals bringing over 60 years combined experience from organizations such as NASA, the University of Alabama at Birmingham, and Mississippi State University. Soluble Therapeutics, Inc. is the first company to introduce protein formulation solutions that deliver the price and performance advantages of the HSC™ Technology.
For additional information visit www.soluble-therapeutics.com
SOURCE Soluble Therapeutics, Inc.